Funding for psilocybin research was recently awarded to the Indiana University School of Medicine’s Department of Psychiatry by the Indiana Family and Social Services Administration from the Therapeutic Psilocybin Research Fund, established by 2024 Indiana legislation. 

Michelle Galen, MD, and her husband, Juan Cabrara, MD, both members of ISMA, have developed a survey to assess physicians' awareness and perceptions of these new treatments.  Dr. Galen is a family physician, and Dr. Cabrara is a psychiatrist.
They are asking ISMA physicians to take the survey.

Longtime ISMA member and psilocybin research proponent Richard Feldman, MD, noted that this is the next step in the possibility of psychedelic treatment for emotional issues and addiction in Indiana. 
“Even a single dose given under strict medical protocols can treat resistant depression, anxiety, PTSD, and other conditions…. and have long-lasting benefits for months and even years,” Dr. Feldman said. “For this reason, I became involved with the legislation.  This is not fringe medicine and is, although still novel, becoming mainstream.”

Indiana passed Senate Bill 139 in 2024, which established the Therapeutic Psilocybin Research Fund to provide financial assistance to research institutions in the state for studying psilocybin’s use in treating mental health and other medical conditions. In 2025, the legislation was expanded to include ibogaine research.